[1] Grüner N, Mattner J. Bile acids and microbiota: multifaceted and versatile regulators of the liver-gut axis[J]. Int J Mol Sci,2021,22(3):1397.
[2] Kassa Y, Million Y, Gedefie A, et al. Alteration of gut microbiota and its impact on immune response in patients with chronic HBV infection: a review[J]. Infect Drug Resist,2021,14:2571-2578.
[3] Joo E J, Cheong H S, Kwon M J, et al. Relationship between gut microbiome diversity and hepatitis B viral load in patients with chronic hepatitis B[J]. Gut Pathog,2021,13(1):65.
[4] Liu Y. Effect of intestinal microbiota imbalance associated with chronic hepatitis B virus infection on the expression of microRNA192 and GLP1[J]. Mol Med Rep,2021,24(3):662.
[5] Wang K, Zhang Z, Mo Z S, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure[J]. Gut Microbes,2021,13(1):1-15.
[6] Sultan S, El-Mowafy M, Elgaml A, et al. Alterations of the treatment-naive gut microbiome in newly diagnosed hepatitis C virus infection[J]. ACS Infect Dis,2021,7(5):1059-1068.
[7] Honda T, Ishigami M, Yamamoto K, et al. Changes in the gut microbiota after hepatitis C virus eradication[J]. Sci Rep,2021,11(1):23568.
[8] Inoue T, Funatsu Y, Ohnishi M, et al. Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection[J]. Liver Int,2022,42(1):124-134.
[9] Wu J, Bortolanza M, Zhai G, et al. Gut microbiota dysbiosis associated with plasma levels of Interferon-γ and viral load in patients with acute hepatitis E infection[J]. J Med Virol,2022,94(2):692-702.
[10] Kong L, Chen J, Ji X, et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance[J]. J Exp Clin Cancer Res,2021,40(1):18.
[11] Litwinowicz K, Gamian A. Microbiome alterations in alcohol use disorder and alcoholic liver disease[J]. Int J Mol Sci,2023,24(3):2461.
[12] Kim S S, Eun J W, Cho H J, et al. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis[J]. Aliment Pharmacol Ther,2021,53(4):540-551.
[13] Seo B, Jeon K, Moon S, et al. Roseburia spp. Abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice[J]. Cell Host Microbe,2020,27(1):25-40.
[14] Sangineto M, Grander C, Grabherr F, et al. Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease[J]. Gut Microbes,2022,14(1):2089006.
[15] Li X, Liu Y, Guo X, et al. Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury[J]. Eur J Clin Nutr,2021,75(8):1227-1236.
[16] Wang Q, Kim S Y, Matsushita H, et al. Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22[J]. Proc Natl Acad Sci U S A,2021,118(1):e2020868118.
[17] Jiang W, Zhu H, Liu C, et al. In-depth investigation of the mechanisms of Echinacea purpurea polysaccharide mitigating alcoholic liver injury in mice via gut microbiota informatics and liver metabolomics[J]. Int J Biol Macromol,2022,209(Pt A):1327-1338.
[18] Maslennikov R, Ivashkin V, Efremova I,et al. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis[J]. World J Gastroenterol,2022,28(10):1067-1077.
[19] Tang Y, Zhou H, Xiang Y, et al. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol,2021,33(1S Suppl 1):e167-e175.
[20] Shu W, Shanjian C, Jinpiao L,et al. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis[J]. Ann Hepatol,2022,27(2):100676.
[21] Han W, Huang C, Zhang Q, et al. Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid[J]. Eur J Clin Invest,2022,52(2):e13714.
[22] Liu X, Wang L, Tan S,et al. Therapeutic effects of berberine on liver fibrosis are associated with lipid metabolism and intestinal flora[J]. Front Pharmacol,2022,13:814871.
[23] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut,2018,67(3):534-541.
[24] Sun L, Cai J, Gonzalez F J. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer[J]. Nat Rev Gastroenterol Hepatol,2021,18(5):335-347.
[25] Feng L, Zhang W, Shen Q, et al. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome[J]. J Cachexia Sarcopenia Muscle,2021,12(6):1553-1569.
[26] Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: a special focus on the role of gut microbiota[J]. Cancer Sci,2021,112(11):4433-4443.
[27] Chen W, Wen L, Bao Y, et al. Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2[J]. Proc Natl Acad Sci U S A,2022,119(52):e2203894119.
[28] Liu X, Chen Y, Zhang S, et al. Gut microbiota-mediated immunomodulation in tumor[J]. J Exp Clin Cancer Res,2021,40(1):221.
[29] Zhang Q, Ma C, Duan Y, et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma[J]. Cancer Discov,2021,11(5):1248-1267.
[30] Behary J, Amorim N, Jiang X T, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun,2021,12(1):187.
[31] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut,2019,68(6):1014-1023.
[32] Ma J, Li J, Jin C, et al. Association of gut microbiome and primary liver cancer: a two-sample Mendelian randomization and case-control study[J]. Liver Int,2023,43(1):221-233.
[33] Yuan N, Li X, Wang M, et al. Gut Microbiota alteration influences colorectal cancer metastasis to the liver by remodeling the liver immune microenvironment[J]. Gut Liver,2022,16(4):575-588.
[34] Hu C, Xu B, Wang X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC[J]. Hepatology,2023,77(1):48-64. |
